| Patent application number | Description | Published |
|---|
| 20080267983 | Peptide Inhibitors for Mediating Stress Responses - The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing peptides recognized by monoclonal anti-DNA antibodies, the peptides having anti-apoptotic and anti-inflammatory activity. The invention further provides antibody molecules and uses thereof for the isolation of such peptides. | 10-30-2008 |
| 20080279878 | Compositions of Hsp60 Peptides and Viral Antigens for Vaccination and Diagnosis - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 11-13-2008 |
| 20090035359 | IMMUNOGENIC FRAGMENTS OF T-CELL RECEPTOR CONSTANT DOMAINS AND PEPTIDES DERIVED THEREFROM - The present invention is directed to an isolated T-Cell Receptor constant domain and to peptides derived therefrom and recombinant constructs encoding same, effective in therapy of T cell mediated inflammatory disease, autoimmunity and graft rejection. Therapeutic and prophylactic vaccine compositions and methods utilizing these proteins and peptides, DNA vaccines encoding same and T cell vaccines thereof are further provided. | 02-05-2009 |
| 20090098116 | IMMUNOGENIC COMPOSITIONS FOR INDUCTION OF ANTI-TUMOR IMMUNITY - The invention relates to the use of an immunogen selected from the group consisting of | 04-16-2009 |
| 20090202618 | Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases - The present invention is related to recombinant constructs encoding active fragments of HSP60 which are effective in treating T cell-mediated inflammatory autoimmune diseases by DNA vaccines. The HSP60 fragments of the present invention are identified by their ability to react with T cells isolated from an animal vaccinated with DNA constructs encoding HSP70 to induce Th2/3 T-cell responses. | 08-13-2009 |
| 20090238864 | DNA VACCINES ENCODING HEAT SHOCK PROTEINS - The present invention is related to a method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 60 (HSP60), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences, and wherein the disease is other than insulin dependent diabetes mellitus (IDDM), thereby treating the disease. | 09-24-2009 |
| 20090269370 | VACCINES COMPRISING MULTIMERIC HSP60 PEPTIDE CARRIERS - The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided. | 10-29-2009 |
| 20090270312 | HIV-I GP41 FUSION PEPTIDES FOR IMMUNOMODULALTION - The present invention provides pharmaceutical compositions and methods for prevention or treatment of autoimmune diseases and other T cell mediated inflammatory diseases and conditions, which comprise as an active ingredient an effective quantity of a peptide derived from HIV gp41 fusion peptide domain or fragments, analogs, homologs and derivatives thereof. The invention further provides novel peptides derived from HIV gp41 fusion peptide domain, useful in the treatment of T cell mediated pathologies. | 10-29-2009 |
| 20090275503 | DIASTEREOMERIC PEPTIDES FOR MODULATING T CELL IMMUNITY - The present invention provides diastereomeric peptides derived from the T Cell Receptor alpha Transmembrane Domain, and lipophilic conjugates thereof, which peptides and conjugates are effective in preventing or treating T cell mediated inflammatory diseases. The invention provides pharmaceutical compositions comprising these diastereomeric peptides and conjugates, and uses thereof for therapy of inflammatory diseases, autoimmunity and graft rejection. | 11-05-2009 |
| 20100003225 | HSP60, HSP60 PEPTIDES AND T CELL VACCINES FOR IMMUNOMODULATION - The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders. | 01-07-2010 |
| 20100189750 | METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES - A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject. | 07-29-2010 |
| 20100304483 | T-CELL VACCINATION IN THE TREATMENT OF HIV INFECTION - A method for the preparation of a T cell vaccine for the treatment of immunodeficient HIV-infected patients is described herein, based on the enrichment of autologous CD4-reactive CD8 T cells. Also described is a protocol for the implementation of T cell vaccination in immunodeficient HIV-infected, as well as a method of treatment, based on the T cell vaccine developed herein. Finally, kits for preparing the T cell vaccine as well as for implementing the protocol are also provided. | 12-02-2010 |
| 20110076323 | VACCINE FOR ALZHEIMER'S DISEASE - Compositions and methods for prevention and treatment of Alzheimer's disease utilize a combination of amyloid-beta protein or a fragment thereof and a heat shock protein or a fragment thereof. | 03-31-2011 |
